At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 122 enrolled
Drug / intervention
Avatrombopag +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers
In Brief
A Phase 3 clinical trial evaluating Avatrombopag and Placebo Oral Tablet for Chemotherapy-induced Thrombocytopenia. Completed, enrolled 122 participants across 55 sites in 7 countries.
Detailed Summary
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Thrombocytopenia
CountriesChina, Hungary, Poland, Russia, Serbia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartOct 2018
Primary CompletionAug 2020
Study CompletionJan 2023
TodayJul 2026
First PostedMar 20, 2018
Enrollment StartOct 12, 2018
Primary CompletionAug 28, 2020
Study CompletionJan 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.3 years ago
Interventions
Avatrombopagdrug
Oral avatrombopag tablet
Placebo Oral Tabletdrug
Placebo comparator tablet